Trials / Unknown
UnknownNCT03313661
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Evaluation of the glycemic efficacy of cabergoline on diabetic patients
Detailed description
Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long acting D2 agonist, is expected to play a role in the glycemic control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabergoline | cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide |
| DRUG | Gliclazide | gliclazide (60-120 mg) |
Timeline
- Start date
- 2017-10-14
- Primary completion
- 2020-10-01
- Completion
- 2020-12-01
- First posted
- 2017-10-18
- Last updated
- 2018-08-27
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03313661. Inclusion in this directory is not an endorsement.